<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E544F78A-9018-4CFF-BABB-B54D48465F19"><gtr:id>E544F78A-9018-4CFF-BABB-B54D48465F19</gtr:id><gtr:firstName>Rachel</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Abbotts</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000252"><gtr:id>F87C0A80-0A86-417D-B386-7E03D5102570</gtr:id><gtr:title>Therapeutic potential of human apurinic/apyrimidinic endonuclease 1 (APE1) modulation in melanoma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1000252</gtr:grantReference><gtr:abstractText>Chemotherapy and radiation therapy are commonly used to treat melanoma. However many melanomas are resistant to such treatments because the cancer cells are able to counteract the effects of therapy by utilising the DNA repair machinery to repair DNA damage induced by these agents. The focus of my research is to develop drugs to block DNA repair in cells and thereby enhance cancer cell death. This will lead to better response to treatments and improve patient outcomes. 

My research will focus on APE1, an essential protein involved in DNA base excision repair. The host laboratory has developed compounds that can inhibit APE1 and I will evaluate the effects of these compounds in melanoma. In addition I will study the biological function of APE1 in melanoma by manipulating APE1 gene expression in melanoma using a variety of techniques.

The proposal brings together leading research groups with complementary expertise to find new ways of treating melanoma.</gtr:abstractText><gtr:technicalSummary>DNA repair mechanisms that operate in cancer cells rectify DNA damage induced by therapeutic agents and contribute significantly to resistance in melanoma and impact negatively on patient outcomes. Human apurinic/apyrimidinic endonuclease (APE1) is a key player in DNA base excision repair and has been linked to radio- and chemo-resistance. The host laboratory has an ongoing drug discovery programme and has isolated several novel APE1 inhibitors for pharmaceutical application. This proposal aims to investigate the potential of APE1 inhibitors in melanoma.

Aims
1) Evaluate the therapeutic potential of APE1 inhibitors in melanoma. 
2) Understand the mechanism of action of APE1 inhibitors. 
3) Investigate the biological consequence of APE1 gene alterations in melanoma.

Objectives 
1) To show that APE1 inhibitors potentiate the cytotoxicity of temozolomide, cisplatin and ionising radiation in melanoma cell lines and blockage of APE1 delays DNA repair and alters cell cycle progression in cells. 
2) To test if the inhibitors are competitive or non-competitive inhibitors and investigate differential activity against polymorphic variants of APE1. 
3) To evaluate phenotypic consequences of APE1 gene alterations in melanoma cell lines and evaluate clinicopathological significance of APE1 expression in human melanoma tumours. 

Design and methodology

Biochemical and molecular biological investigations: Investigate whether the inhibitors are competitive or non-competitive by the measurement of overall enzyme catalytic rate (kcat) and the concentration of substrate that permits half maximal rate of reaction (Km).Investigate whether the inhibitors disrupt protein-DNA complex formation using the standard electrophoretic mobility shift assays. To reveal which amino acids of APE1 are interacting with the small molecule by investigating the effects of certain inhibitors on a variety of APE1 active site mutants and polymorphic variants. 

Cell biology and APE1 expression investigations: Investigate 10 novel inhibitors in a panel of 10 melanoma cell lines using MTS and clonogenic assays. Test for intrinsic cytotoxicity and for potentiation of cytotoxicity of temozolomide, cisplatin and ionising radiation. APE1 inhibition will be confirmed by quantifying AP site accumulation in cells (Aldehyde Reactive Probe), DNA repair kinetics (COMET assay) and cell cycle progression. Phenotypic effects will be investigated using cell proliferation, migration and invasion assays. APE1 gene manipulation [gene silencing and overexpression] to complement small molecule studies. Investigate clinicopathological significance of APE1 gene expression (Illumina?s DASL array) and protein expression (immunohistochemistry) in 200 tumours. 

Scientific and medical opportunities
This proposal could enhance our knowledge of APE1 biology in cancer and lead to a novel treatment strategy for melanoma.</gtr:technicalSummary><gtr:fund><gtr:end>2013-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>192108</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C020F848-2948-433D-A9BF-AB96A4772DF8</gtr:id><gtr:title>Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f79e0aad6f0df9346abb14e077c0cdd"><gtr:id>2f79e0aad6f0df9346abb14e077c0cdd</gtr:id><gtr:otherNames>Al-Attar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14708_28_20087352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11BA171D-2770-4E9E-AAD2-6B6F30875672</gtr:id><gtr:title>Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51e00926fe1269d9c2ed16552f7a76e6"><gtr:id>51e00926fe1269d9c2ed16552f7a76e6</gtr:id><gtr:otherNames>Abbotts R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>pm_14708_28_20056333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9649887-F23D-4CAE-BA98-CF658BC0D434</gtr:id><gtr:title>Base excision repair factors are promising prognostic and predictive markers in cancer.</gtr:title><gtr:parentPublicationTitle>Current molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/115c56719351714fb66e53156e14c31f"><gtr:id>115c56719351714fb66e53156e14c31f</gtr:id><gtr:otherNames>Gossage L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1874-4672</gtr:issn><gtr:outcomeId>pm_14708_28_22122468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F969350A-FCBF-4E1C-A426-63F0EDD5C7C5</gtr:id><gtr:title>Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ce3064911a05271904fe6445b9e168b"><gtr:id>0ce3064911a05271904fe6445b9e168b</gtr:id><gtr:otherNames>Mohammed MZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_14708_28_21266972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC812601-559A-4C58-82C7-42226B83294C</gtr:id><gtr:title>Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51e00926fe1269d9c2ed16552f7a76e6"><gtr:id>51e00926fe1269d9c2ed16552f7a76e6</gtr:id><gtr:otherNames>Abbotts R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>pm_540e172e1720d7bc6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>672600C9-DAF2-4849-B528-22C4A5E02C7E</gtr:id><gtr:title>Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/517aebfddb20c2c2c29b535b3547f2bd"><gtr:id>517aebfddb20c2c2c29b535b3547f2bd</gtr:id><gtr:otherNames>Sultana R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>pm_14708_28_22377908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8E8C7AB-EADC-4C07-B666-544D4799AD13</gtr:id><gtr:title>Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3f930c0ca29c6f0ee9a1b0017e4d824"><gtr:id>d3f930c0ca29c6f0ee9a1b0017e4d824</gtr:id><gtr:otherNames>Abdel-Fatah T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>pm_14708_28_22894650</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000252</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>